Company intelligence / Profile preview
Iovance Biotherapeutics
San Carlos, California, United Statesiovance.com ↗
- Ownership
- Public · IOVA
- Employees
- ~750
- Development stage
- Commercial
01
Overview
Amtagvi™/lifileucel became the first FDA-approved T-cell therapy for a solid tumor indication. The company has demonstrated promising clinical data across multiple solid tumors with its TIL platform. Early commercial launch of Amtagvi generated $31.1 million revenue in Q2'24 with strong growth guidance into FY25 ($450–$475M projected). Additional pipeline programs are advancing through clinical trials.
- Therapeutic areas
- Oncology
- Modalities
- Tumor infiltrating lymphocytes (TIL) therapy (autologous cell therapy)Genetically modified TIL therapies (in development)Peripheral blood lymphocyte (PBL) therapy for blood cancersInterleukin-based therapies (Proleukin/aldesleukin)
- Industry
- Biotech
02
Drug pipeline
25 assets24 more assets in the full pipeline.
03
Financials
- Market cap
- $3.5B
- Total revenue
- $263.5M
- Enterprise value
- $3.2B
Beyond the preview
Go deeper on Iovance Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Iovance Biotherapeutics.